Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Loss of MTUS1/ATIP expression is associated with adverse outcome in advanced bladder carcinomas: data from a retrospective study

Authors: Anja Rogler, Sabine Hoja, Johannes Giedl, Arif B Ekici, Sven Wach, Helge Taubert, Peter J Goebell, Bernd Wullich, Michael Stöckle, Jan Lehmann, Sabrina Petsch, Arndt Hartmann, Robert Stoehr

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Seventy percent of all bladder tumours tend to recur and need intensive surveillance, and a subset of tumours progress to muscle-invasive and metastatic disease. However, it is still difficult to find the adequate treatment for every individual patient as it is a very heterogeneous disease and reliable biomarkers are still missing. In our study we searched for new target genes in the critical chromosomal region 8p and investigated the potential tumour suppressor gene candidate MTUS1/ATIP in bladder cancer.

Methods

MTUS1 was identified to be the most promising deleted target gene at 8p in aCGH analysis with 19 papillary bladder tumours. A correlation with bladder cancer was further validated using immunohistochemistry of 85 papillary and 236 advanced bladder tumours and in functional experiments. Kaplan-Meier analysis and multivariate Cox-regression addressed overall survival (OS) and disease-specific survival (DSS) as a function of MTUS1/ATIP expression. Bivariate correlations investigated associations between MTUS1/ATIP expression, patient characteristics and histopathology. MTUS1 expression was analysed in cell lines and overexpressed in RT112, where impact on viability, proliferation and migration was measured.

Results

MTUS1 protein expression was lost in almost 50% of all papillary and advanced bladder cancers. Survival, however, was only influenced in advanced carcinomas, where loss of MTUS1 was associated with adverse OS and DSS. In this cohort, there was also a significant correlation of MTUS1 expression and histological subtype: positive expression was detected in all micropapillary tumours and aberrant nuclear staining was detected in a subset of plasmocytoid urothelial carcinomas. MTUS1 was expressed in all investigated bladder cell lines and overexpression in RT112 led to significantly decreased viability.

Conclusions

MTUS1 is a tumour suppressor gene in cultured bladder cancer cells and in advanced bladder tumours. It might represent one new target gene at chromosome 8p and can be used as an independent prognostic factor for advanced bladder cancer patients. The limitation of the study is the retrospective data analysis. Thus, findings should be validated with a prospective advanced bladder tumour cohort.
Appendix
Available only for authorised users
Literature
1.
Reinert T, Modin C, Castano FM, Lamy P, Wojdacz TK, Hansen LL, Wiuf C, Borre M, Dyrskjot L, Orntoft TF: Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin Cancer Res. 2011, 17: 5582-5592. 10.1158/1078-0432.CCR-10-2659.CrossRefPubMed
2.
Fristrup N, Ulhoi BP, Birkenkamp-Demtroder K, Mansilla F, Sanchez-Carbayo M, Segersten U, Malmstrom PU, Hartmann A, Palou J, Alvarez-Mugica M, Zieger K, Borre M, Ornthoft TF, Dyrskjot L: Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. Am J Pathol. 2012, 180: 1824-1834. 10.1016/j.ajpath.2012.01.023.CrossRefPubMed
3.
Park SJ, Lee TJ, Chang IH: Role of the mTOR pathway in the progression and recurrence of bladder cancer: an immunohistochemical tissue microarray study. Korean J Urol. 2011, 52: 466-473. 10.4111/kju.2011.52.7.466.CrossRefPubMedPubMedCentral
4.
Munksgaard PP, Mansilla F, Brems Eskildsen AS, Fristrup N, Birkenkamp-Demtroder K, Ulhoi BP, Borre M, Agerbaek M, Hermann GG, Orntoft TF, Dyrskjot L: Low ANXA10 expression is associated with disease aggressiveness in bladder cancer. Br J Cancer. 2011, 105: 1379-1387. 10.1038/bjc.2011.404.CrossRefPubMedPubMedCentral
5.
Gui Y, Guo G, Huang Y, Hu X, Tang A, Gao S, Wu R, Chen C, Li X, Zhou L, He M, Li Z, Sun X, Jia W, Chen J, Yang S, Zhou F, Zhao X, Wan S, Ye R, Liang C, Liu Z, Huang P, Liu C, Jiang H, Wang Y, Zheng H, Sun L, Liu X, Jiang Z, et al: Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet. 2011, 43: 875-878. 10.1038/ng.907.CrossRefPubMed
6.
Wolff EM, Liang G, Jones PA: Mechanisms of disease: genetic and epigenetic alterations that drive bladder cancer. Nat Clin Pract Urol. 2005, 2: 502-510.CrossRefPubMed
7.
Williams SV, Platt FM, Hurst CD, Aveyard JS, Taylor CF, Pole JC, Garcia MJ, Knowles MA: High-resolution analysis of genomic alteration on chromosome arm 8p in urothelial carcinoma. Genes Chromosomes Cancer. 2010, 49: 642-659.PubMed
8.
Stoehr R, Wissmann C, Suzuki H, Knuechel R, Krieg RC, Klopocki E, Dahl E, Wild P, Blaszyk H, Sauter G, Simon R, Schmitt R, Zaak D, Hofstaedter F, Rosenthal A, Baylin SB, Pilarsky C, Hartmann A: Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest. 2004, 84: 465-478. 10.1038/labinvest.3700068.CrossRefPubMed
9.
Lehmann J, Retz M, Wiemers C, Beck J, Thuroff J, Weining C, Albers P, Frohneberg D, Becker T, Funke PJ, Walz P, Langbein S, Reiher F, Schiller M, Miller K, Roth S, Kälble T, Sternberg D, Wellek S, Stöckle M: Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol. 2005, 23: 4963-4974. 10.1200/JCO.2005.11.094.CrossRefPubMed
10.
Hatina J, Huckenbeck W, Rieder H, Seifert HH, Schulz WA: Bladder carcinoma cell lines as models of the pathobiology of bladder cancer. Review of the literature and establishment of a new progression series. Urologe A. 2008, 47: 724-734. 10.1007/s00120-008-1687-4.CrossRefPubMed
11.
Masters JR, Hepburn PJ, Walker L, Highman WJ, Trejdosiewicz LK, Povey S, Parkar M, Hill BT, Riddle PR, Franks LM: Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines. Cancer Res. 1986, 46: 3630-3636.PubMed
12.
Rieger KM, Little AF, Swart JM, Kastrinakis WV, Fitzgerald JM, Hess DT, Libertino JA, Summerhayes IC: Human bladder carcinoma cell lines as indicators of oncogenic change relevant to urothelial neoplastic progression. Br J Cancer. 1995, 72: 683-690. 10.1038/bjc.1995.394.CrossRefPubMedPubMedCentral
13.
Tzeng CC, Liu HS, Li C, Jin YT, Chen RM, Yang WH, Lin JS: Characterization of two urothelium cancer cell lines derived from a blackfoot disease endemic area in Taiwan. Anticancer Res. 1996, 16: 1797-1804.PubMed
14.
Rossi MR, Masters JR, Park S, Todd JH, Garrett SH, Sens MA, Somji S, Nath J, Sens DA: The immortalized UROtsa cell line as a potential cell culture model of human urothelium. Environ Health Perspect. 2001, 109: 801-808. 10.1289/ehp.01109801.CrossRefPubMedPubMedCentral
15.
Riesenberg R, Fuchs C, Kriegmair M: Photodynamic effects of 5-aminolevulinic acid-induced porphyrin on human bladder carcinoma cells in vitro. Eur J Cancer. 1996, 32A: 328-334.CrossRefPubMed
16.
Ottesen SS, Ahrenkiel V, Kieler J: Recombinant human interferon gamma exerts an anti-proliferative effect and modulates the expression of human leukocyte antigens A, B, C and DR in human urothelial cell lines. Cancer Immunol Immunother. 1990, 31: 93-98. 10.1007/BF01742372.CrossRefPubMed
17.
Pape GR, Troye M, Perlmann P: Heterogeneity and mechanism of action of human natural killer lymphocytes: differential distribution of receptors for Helix pomatia haemagglutinin (HP receptors). Scand J Immunol. 1979, 10: 109-118. 10.1111/j.1365-3083.1979.tb03265.x.CrossRefPubMed
18.
Larsen JK, Christensen IJ, Kieler J: Cell cycle perturbation by sodium butyrate in tumorigenic and non-tumorigenic human urothelial cell lines assessed by flow cytometric bromodeoxyuridine/DNA analysis. Cell Prolif. 1995, 28: 359-371. 10.1111/j.1365-2184.1995.tb00078.x.CrossRefPubMed
19.
Louis SN, Chow L, Rezmann L, Krezel MA, Catt KJ, Tikellis C, Frauman AG, Louis WJ: Expression and function of ATIP/MTUS1 in human prostate cancer cell lines. Prostate. 2010, 70: 1563-1574. 10.1002/pros.21192.CrossRefPubMed
20.
Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008, 3: 1101-1108. 10.1038/nprot.2008.73.CrossRefPubMed
21.
Koufou S, Lunz JC, Borchardt A, Keck B, Kneitz B, Gaisa NT, Hafner C, Giedl C, Rau TT, Rogler A, Wieland WF, Hartmann A, Stoehr R: Mutational activation of FGFR3 is not involved in the development of prostate cancer. Pathobiology. 2010, 77: 249-252. 10.1159/000317055.CrossRefPubMed
22.
Van Oers JM, Lurkin I, Van Exsel AJ, Nijsen Y, Van Rhijn BW, van der Aa MN, Zwarthoff EC: A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res. 2005, 11: 7743-7748. 10.1158/1078-0432.CCR-05-1045.CrossRefPubMed
23.
Hafner C, Van Oers JM, Vogt T, Landthaler M, Stoehr R, Blaszyk H, Hofstaedter F, Zwarthoff EC, Hartmann A: Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J Clin Invest. 2006, 116: 2201-2207. 10.1172/JCI28163.CrossRefPubMedPubMedCentral
24.
Bubendorf L, Nocito A, Moch H, Sauter G: Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol. 2001, 195: 72-79. 10.1002/path.893.CrossRefPubMed
25.
Klopocki E, Kristiansen G, Wild PJ, Klaman I, Castanos-Velez E, Singer G, Stohr R, Simon R, Sauter G, Leibiger H, Essers L, Weber B, Hermann K, Rosenthal A, Hartmann A, Dahl E: Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol. 2004, 25: 641-649.PubMed
26.
Seibold S, Rudroff C, Weber M, Galle J, Wanner C, Marx M: Identification of a new tumor suppressor gene located at chromosome 8p21.3-22. FASEB J. 2003, 17: 1180-1182.PubMed
27.
Pils D, Horak P, Gleiss A, Sax C, Fabjani G, Moebus VJ, Zielinski C, Reinthaller A, Zeillinger R, Krainer M: Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival. Cancer. 2005, 104: 2417-2429. 10.1002/cncr.21538.CrossRefPubMed
28.
Zuern C, Heimrich J, Kaufmann R, Richter KK, Settmacher U, Wanner C, Galle J, Seibold S: Down-regulation of MTUS1 in human colon tumors. Oncol Rep. 2010, 23: 183-189.PubMed
29.
Rodrigues-Ferreira S, Di Tommaso A, Dimitrov A, Cazaubon S, Gruel N, Colasson H, Nicolas A, Chaverot N, Molinie V, Reyal F, Sigal-Zafrani B, Terris B, Delattre O, Radnanyi F, Perez F, Vincent-Salomon A, Nahmias C: 8p22 MTUS1 gene product ATIP3 is a novel anti-mitotic protein underexpressed in invasive breast carcinoma of poor prognosis. PLoS One. 2009, 4: e7239-10.1371/journal.pone.0007239.CrossRefPubMedPubMedCentral
30.
Xiao J, Chen JX, Zhu YP, Zhou LY, Shu QA, Chen LW: Reduced expression of MTUS1 mRNA is correlated with poor prognosis in bladder cancer. Oncol Lett. 2012, 4: 113-118.PubMedPubMedCentral
31.
Knowles MA, Shaw ME, Proctor AJ: Deletion mapping of chromosome 8 in cancers of the urinary bladder using restriction fragment length polymorphisms and microsatellite polymorphisms. Oncogene. 1993, 8: 1357-1364.PubMed
32.
Takle LA, Knowles MA: Deletion mapping implicates two tumor suppressor genes on chromosome 8p in the development of bladder cancer. Oncogene. 1996, 12: 1083-1087.PubMed
33.
Choi C, Kim MH, Juhng SW, Oh BR: Loss of heterozygosity at chromosome segments 8p22 and 8p11.2-21.1 in transitional-cell carcinoma of the urinary bladder. Int J Cancer. 2000, 86: 501-505. 10.1002/(SICI)1097-0215(20000515)86:4<501::AID-IJC9>3.0.CO;2-#.CrossRefPubMed
34.
Rodrigues-Ferreira S, Nahmias C: An ATIPical family of angiotensin II AT2 receptor-interacting proteins. Trends Endocrinol Metab. 2010, 21: 684-690. 10.1016/j.tem.2010.08.009.CrossRefPubMed
35.
Nouet S, Amzallag N, Li JM, Louis S, Seitz I, Cui TX, Alleaume AM, Di Benedetto M, Boden C, Masson M, Strosberg AD, Horiuchi M, Couraud PO, Nahmias C: Trans-inactivation of receptor tyrosine kinases by novel angiotensin II AT2 receptor-interacting protein, ATIP. J Biol Chem. 2004, 279: 28989-28997. 10.1074/jbc.M403880200.CrossRefPubMed
36.
Molina A, Velot L, Ghouinem L, Abdelkarim M, Bouchet BP, Luissint AC, Bouhlel I, Morel M, Sapharikas E, Di Tommaso A, Honore S, Braquer D, Gruel N, Vincent-Salomon A, Delattre O, Sigal-Zafrani B, Andre F, Terris B, Akhmanova A, Di Benedetto M, Nahmias C, Rodriques-Ferreira S: ATIP3, a novel prognostic marker of breast cancer patient survival, limits cancer cell migration and slows metastatic progression by regulating microtubule dynamics. Cancer Res. 2013, 73: 2905-2915. 10.1158/0008-5472.CAN-12-3565.CrossRefPubMed
37.
Di Benedetto M, Bieche I, Deshayes F, Vacher S, Nouet S, Collura V, Seitz I, Louis S, Pineau P, Amsellem-Ouazana D, Couraud PO, Strosberg AD, Stoppa-Lyonnet D, Lidereau R, Nahmias C: Structural organization and expression of human MTUS1, a candidate 8p22 tumor suppressor gene encoding a family of angiotensin II AT2 receptor-interacting proteins, ATIP. Gene. 2006, 380: 127-136. 10.1016/j.gene.2006.05.021.CrossRefPubMed
38.
Di Benedetto M, Pineau P, Nouet S, Berhouet S, Seitz I, Louis S, Dejean A, Couraud PO, Strosberg AD, Stoppa-Lyonnet D, Nahmias C: Mutation analysis of the 8p22 candidate tumor suppressor gene ATIP/MTUS1 in hepatocellular carcinoma. Mol Cell Endocrinol. 2006, 252: 207-215. 10.1016/j.mce.2006.03.014.CrossRefPubMed
Metadata
Title
Loss of MTUS1/ATIP expression is associated with adverse outcome in advanced bladder carcinomas: data from a retrospective study
Authors
Anja Rogler
Sabine Hoja
Johannes Giedl
Arif B Ekici
Sven Wach
Helge Taubert
Peter J Goebell
Bernd Wullich
Michael Stöckle
Jan Lehmann
Sabrina Petsch
Arndt Hartmann
Robert Stoehr
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-214

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

Tumor-stroma metabolic relationship based on lactate shuttle can sustain prostate cancer progression

Research article

Myofibroblastic stromal reaction and lymph node status in invasive breast carcinoma: possible role of the TGF-β1/TGF-βR1 pathway

Research article

MicroRNA-26b inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting USP9X

Research article

Systemic neutralization of IL-17A significantly reduces breast cancer associated metastasis in arthritic mice by reducing CXCL12/SDF-1 expression in the metastatic niches

Research article

Identification of prognostic factors and surgical indications for metastatic gastric cancer

Research article

Higher incidence of premenopausal breast cancer in less developed countries; myth or truth?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits